Illumina (ILMN) Earnings Date & Reports

Key Takeaways

• Illumina reported third-quarter fiscal 2026 revenue of $1.13 billion, up 4.2% from $1.08 billion a year earlier, though slightly below the roughly $1.15 billion consensus on a reported basis.
• Adjusted (non-GAAP) diluted earnings per share (EPS) rose 7% to $1.44, topping the $1.36 analysts expected.
• Revenue excluding one-time tariff refunds was $1.17 billion, above the $1.15 billion estimate.
• Non-GAAP operating margin improved to 25.0%, and free cash flow climbed to $378 million from $253 million a year earlier.
• Management raised full-year 2026 guidance to revenue of $4.64 billion–$4.66 billion and adjusted EPS of $5.40–$5.45.
• Despite the beat, shares slid roughly 12% in after-hours trading as investors focused on China and softer research-market demand.
• For more information about Illumina's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Explore Trending AI Robots to discover AI-powered trading ideas across the market.

Earnings Context and Why It Matters

Illumina is the leading maker of DNA sequencing systems used by research institutions, clinical labs, pharmaceutical companies, and genomics providers. This quarterly report matters because it serves as a key read on the company's transition to its flagship NovaSeq X platform, the balance between resilient clinical demand and a still-soft research market, and management's push beyond hardware into software, artificial intelligence (AI), and data. Coming into the report, the stock had surged roughly 120% year to date, raising the bar for what investors needed to hear. The results confirmed strengthening margins and cash flow, but a sharp after-hours selloff signaled that the market was looking for clearer evidence of accelerating growth.

Reported Results

For the third quarter of fiscal 2026, ended September 27, 2026, Illumina reported revenue of $1.13 billion, up 4.2% from $1.08 billion in the prior-year period. On a non-GAAP basis excluding tariff refunds, revenue was $1.17 billion, topping the roughly $1.15 billion consensus estimate.

GAAP (Generally Accepted Accounting Principles) diluted EPS was $1.43, up from $0.98 a year earlier, while adjusted (non-GAAP) diluted EPS reached $1.44, a 7% increase from $1.34 and above the $1.36 consensus. Net income climbed to $220 million from $150 million a year ago.

Profitability improved across the board. Non-GAAP gross margin expanded 20 basis points to 69.4%, and non-GAAP operating margin rose to 25.0%. Free cash flow reached $378 million, up from $253 million in the prior-year quarter.

By segment, sequencing consumables revenue grew 6% to $792 million, driven by 14% growth in clinical markets, while research-and-applied consumables declined 6%. Sequencing instruments revenue fell 2% organically to $106 million, and sequencing service and other revenue rose 8% to $158 million.

Management raised its full-year 2026 outlook to revenue of $4.64 billion–$4.66 billion and adjusted EPS of $5.40–$5.45, and guided fourth-quarter revenue to $1.22 billion–$1.24 billion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following earnings-driven moves like Illumina's, the AI Screener offers a streamlined way to surface new ideas and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Illumina's headline beat failed to satisfy investors. Shares closed the regular session at $290.06, up 0.44%, before falling roughly 12% in after-hours trading to around $255.88. The decline came despite EPS and revenue (excluding tariff refunds) beating consensus and an upward revision to full-year guidance.

The selloff reflected several concerns rather than the headline numbers themselves. China revenue declined 0.1% during the quarter, research-and-applied consumables continued to contract, and sequencing instruments revenue slipped on an organic basis. With the stock near its 52-week high ahead of the report, elevated expectations left little room for anything short of a stronger growth signal. Investors also appeared to want more clarity on the 2027 outlook, which management said it would provide with fourth-quarter results.

Forward Outlook and Key Factors to Monitor

Looking ahead, Illumina's trajectory will hinge on a few key themes. First is the NovaSeq X transition. Management said roughly 84% of high-throughput volume and 60% of revenue now sit on the X platform, with research-and-applied conversion largely complete. The remaining clinical conversion is expected to reach 80%–85% in coming quarters, which should reduce year-over-year pricing headwinds into 2027.

Second, investors should watch the divergence between clinical and research demand. Clinical consumables grew 14%, while research-and-applied consumables declined 6%. A sustained recovery in research spending would provide a meaningful catalyst, and management noted early signs that research activity is stabilizing.

Third, the company's newer software and data initiatives — including the Billion Cell Atlas and BioInsight platform — are increasingly central to its strategy. These efforts are still early and not yet a major financial contributor, but management expects them to become more visible in 2027 and beyond.

Finally, China and tariff-related dynamics remain watch items. Tariff refunds provided a one-time benefit to margins and EPS in the quarter that is not expected to repeat, making the underlying operating performance the more relevant measure for future quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations